Field Notes · Medical & Life Sciences
Inovio Creates HIV Breakthrough
On November 22, 2017, Inovio Pharmaceuticals announced that its HIV vaccine, PENNVAX-GP, produced amongst the highest overall levels of immune response rates ever demonstrated in a human study by an HIV vaccine.
Source: Inovio Pharmaceuticals press release
On November 22, 2017, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP, consists of a combination of four HIV antigens designed to cover multiple global HIV strains and generate both an antibody (humoral) immune response as well as a T cell (cellular) immune response to both potentially prevent and treat HIV.
RKS designed and engineered the VGX DNA vaccine delivery platform for VGX/Inovio, transforming an animal-only delivery system into a platform designed for FDA approval and human clinical use.


